Topical Cyclosporine and Disease Progression

Phase 4

Completed

• Conditions: Disease Progression; Disease Severity; Staining; Schirmers; OSDI
• Interventions: Drug: Restasis; Drug: Endura

• Registration Number: NCT00567983
• Lead Sponsor: Innovative Medical

Brief Summary

The purpose of this study is to evaluate the effect Restasis has in regards to disease progression.

Detailed Description

Not available

Study Timeline

• Study Start: 2007-12
• Study First Submitted: 2007-12-03
• Study First Submitted QC: 2007-12-04
• Study First Posted: 2007-12-05
• Status Verified: 2008-09
• Primary Completion: 2008-09
• Study Completion: 2008-09
• Last Update Submitted: 2008-09-23
• Last Update Posted: 2008-09-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

• Mild to Moderate dry eye symptoms

Exclusion Criteria

• Current use of Restasis

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
1.	Restasis	-
2.	Endura	-

Primary Outcome Measures

Name	Time	Method
Disease Severity	1 yr

Secondary Outcome Measures

Name	Time	Method
Staining	1 yr

Trial Locations

Locations (1)

Lakeside Eye Clinic; 🇺🇸 Chicago, Illinois, United States